Menlo Therapeutics Inc

-

Stock Issuer and Owners

Home | Sign Up | Log In
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
Menlo Therapeutics Inc
TickerVYNE
CIK #0001566044
CUSIP92941V308
SectorLife Sciences - Pharmaceutical Preparations
Address200 Cardinal Way, 2Nd Floor, Redwood City, CA 94063
Source [EDGAR]
Reg D Offering (Form D) Filed Raised Terms
VYNE Therapeutics Inc 2023-11-16 88.2 M Exemption: 506(b) · Duration: One year or less · Commission: $5,039,090 · Revenue: Decline to Disclose
Menlo Therapeutics Inc 2017-07-28 50.5 M Exemption: 506(b) · Duration: One year or less · Revenue: Decline to Disclose
Tigercat Pharma Inc 2013-01-07 0.5 M Exemption: 506 · Remaining: $14,500,000 · Duration: One year or less · Revenue: Decline to Disclose
CIK Filing 2011 - 2026
[0001566044] 10-K
[0001566044] 10-Q
[0001566044] 3
[0001566044] 4
[0001566044] 8-K
[0001566044] D
[0001566044] SC 13D
[0001566044] SC 13G
Form 13D/13G Filer Form 13D/13G Subject Filed % Owned
Zhang Xiaofan VYNE Therapeutics Inc [2026-06-15] 0.0
Nantahala Capital Management LLC VYNE Therapeutics Inc [2026-05-15] 0.0
AI Biotechnology LLC VYNE Therapeutics Inc [2023-11-13] 19.99
Eventide Asset Management LLC VYNE Therapeutics Inc [2023-11-13] 0.99
Citadel Advisors LLC VYNE Therapeutics Inc [2023-11-13] 8.5
Cormorant Asset Management LP VYNE Therapeutics Inc [2023-11-13] 9.99
Soleus Capital Master Fund LP VYNE Therapeutics Inc [2023-11-02] 6.4
BlackRock Inc VYNE Therapeutics Inc [2021-02-02] 7.1
Perceptive Advisors LLC Menlo Therapeutics Inc [2020-06-11] 14.0
Point72 Asset Management LP Menlo Therapeutics Inc [2020-01-21] 5.8
Merck Foundation A New Jersey Nonprofit Corp Menlo Therapeutics Inc [2019-02-14] 5.41
First Manhattan Co Menlo Therapeutics Inc [2019-02-11] 5.7
Great Point Partners LLC Menlo Therapeutics Inc [2018-08-13] 6.77
Janus Henderson Group PLC Menlo Therapeutics Inc [2018-05-10] 10.1
Merck & Co Inc Menlo Therapeutics Inc [2018-02-14] 5.41
venBio Global Strategic Fund II LP Menlo Therapeutics Inc [2018-02-08] 6.4
Novo Holdings A/S Menlo Therapeutics Inc [2018-02-08] 5.05
Vivo Capital VIII LLC Menlo Therapeutics Inc [2018-02-02] 17.5
FMR LLC Menlo Therapeutics Inc [2018-01-31] 0.0
Form 3/4/5 Filer 2011 - 2026
Domzalski David
VYNE Therapeutics Inc
Stuart Iain
Zeronda Tyler
Harsch Mutya
Barbari Sharon
Lepore Patrick G
Basta Steven L
Little Elisabeth Sandoval
Bruno Anthony D
Borowski Christine
Access Industries Management LLC
AI Biotechnology LLC
Blavatnik Len
Access Industries Holdings LLC
Perceptive Life Sciences Master Fund Ltd
Edelman Joseph
Perceptive Advisors LLC
Bright Rex
Wiley Matthew T
Saik Andrew
Hirsch Stanley
Hadar Ilan
Ball Kristine M
Krasnow Ronald A
Kwon Paul
McGirr David W J
Whitcup Scott M
Berns Paul L
Royston Aaron
Ebel Ted
Spellman Mary
Watson James F
Sohail Faysal A
Collier David J
CMEA Ventures VII LP
CMEA Ventures VII Parallel LP
Presidio Partners 2007 GP LP
FMR LLC
Cha Albert
venBio Global Strategic Fund II LP
Remeditex Ventures LLC
Vivo Capital Surplus Fund VIII LP
Vivo Capital Fund VIII LP
Vivo Capital VIII LLC
Merck & Co Inc
Merck Sharp & Dohme Corp
Insider Transaction (Form 3/4/5) Date Action Shares Price Value ($)
Zeronda Tyler
Common Stock
2025-12-31 Tax withheld 7,858 $0.58 4,558
Harsch Mutya
Common Stock
2025-12-31 Tax withheld 3,579 $0.58 2,076
Stuart Iain
Common Stock
2025-12-31 Tax withheld 2,448 $0.58 1,420
Domzalski David
Common Stock
2025-12-31 Tax withheld 12,684 $0.58 7,357
Lepore Patrick G
Stock Option (right to buy) · derivative
2025-12-12 Grant 20,000 $0.00
Little Elisabeth Sandoval
Stock Option (right to buy) · derivative
2025-12-12 Grant 20,000 $0.00
Barbari Sharon
Stock Option (right to buy) · derivative
2025-12-12 Grant 20,000 $0.00
Basta Steven L
Stock Option (right to buy) · derivative
2025-12-12 Grant 20,000 $0.00
Zeronda Tyler
Common Stock
2025-09-30 Tax withheld 3,420 $0.34 1,163
Harsch Mutya
Common Stock
2025-09-30 Tax withheld 3,581 $0.34 1,218
Stuart Iain
Common Stock
2025-09-30 Tax withheld 2,453 $0.34 834
Domzalski David
Common Stock
2025-09-30 Tax withheld 12,676 $0.34 4,310
Stuart Iain
Common Stock
2025-06-30 Tax withheld 2,453 $1.65 4,047
Harsch Mutya
Common Stock
2025-06-30 Tax withheld 3,581 $1.65 5,909
Domzalski David
Common Stock
2025-06-30 Tax withheld 12,676 $1.65 20,915
Zeronda Tyler
Common Stock
2025-06-30 Tax withheld 3,420 $1.65 5,643
Harsch Mutya
Common Stock
2025-06-02 Grant 1,145 $0.81 927
Domzalski David
Common Stock
2025-06-02 Grant 8,681 $0.81 7,032
Domzalski David
Common Stock
2025-03-31 Tax withheld 30,498 $1.58 48,187
Stuart Iain
Common Stock
2025-03-31 Tax withheld 6,044 $1.58 9,550
showing 20 of 200 most recent transactions
13F Ownership Over TimeHoldersShares Held
2026-03-31 45 14,418,525
2025-12-31 44 8,206,762
2025-09-30 36 3,977,170
2025-06-30 47 8,102,696
2025-03-31 39 7,161,761
2024-12-31 36 7,064,746
2024-09-30 34 7,702,738
2024-06-30 33 7,978,953
2024-03-31 33 7,839,801
2023-12-31 34 7,902,320
2023-09-30 22 383,586
2023-06-30 21 399,447
Form 13F Holdings
Firm Period DFND Voting Shares
FNY Investment Advisers LLC [2026-06-30] SOLE 35,000 35,000
Prev | Page 1 | Next
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com